Authors
Jingxian Duan, Yuling Wu, Jikui Liu, Jiajia Zhang, Zhichao Fu, Tieshan Feng, Ming Liu, Jie Han, Zhicheng Li, Shifu Chen
Publication date
2019/10/18
Source
Journal of Hepatocellular Carcinoma
Pages
151-166
Publisher
Taylor & Francis
Description
Being one of the most lethal cancers that exhibit high levels of heterogeneity, hepatocellular carcinoma (HCC) is associated with diverse oncogenic pathways underpinned by varied driver genes. HCC can be induced by different etiological factors including virus infection, toxin exposure or metabolic disorders. Consequently, patients may display varied genetic profiles, and may respond differently to the treatments involving inhibition of target pathways. These DNA/RNA mutations, copy number variations, chromatin structural changes, aberrant expression of non-coding RNAs and epigenetic modifications were considered as biomarkers in the application of precision medication. To explore how genetic testing could contribute to early diagnosis, prognosis, treatment and postoperative monitoring of HCC, we conducted a systematic review of genetic markers associated with different pathologies. Moreover, we …
Scholar articles
J Duan, Y Wu, J Liu, J Zhang, Z Fu, T Feng, M Liu… - Journal of Hepatocellular Carcinoma, 2019